千金药业：富马酸伏诺拉生片与恩格列净片获得《药品注册证书》

Core Viewpoint - Qianjin Pharmaceutical has received approval from the National Medical Products Administration for the registration of two new drugs, which may enhance its product portfolio and revenue potential [1] Company Summary - Qianjin Pharmaceutical's subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has been granted drug registration certificates for fumaric acid vonoprazan tablets (20mg, 10mg) and empagliflozin tablets (10mg, 25mg) [1] - As of the latest report, Qianjin Pharmaceutical has a market capitalization of 4.4 billion yuan [1] Revenue Composition - For the first half of 2025, Qianjin Pharmaceutical's revenue composition is as follows: - Pharmaceutical production accounts for 55.83% - Pharmaceutical wholesale and retail accounts for 41.72% - Other industries account for 6.91% - Traditional Chinese medicine materials and decoction pieces production accounts for 1.64% - Internal offsets account for -6.1% [1]